[MO10] Mini-Oral Session 10　Hematologic Malignancies 1（Myeloid）
【E】

[MO10-1] Clinical significance of FLT3 mutations in a comprehensive NGS multicenter study of AML: HM-SCREEN-Japan 01

^○Kentaro Fukushima¹, Hirohiko Shibayama¹, Sunggi Chi², Seiichiro Katagiri³, Akihiko Gotoh³, Takanobu Morishita⁴, Takeshi Kondo⁵, Kazuhito Yamamoto⁶, Jyunya Kuroda⁷, Kensuke Usuki⁸, Yoshimitsu Makoto⁹, Kenji Ishitsuka⁹, Takaaki Ono¹⁰, Naoto Takahashi¹¹, Satoshi Iyama¹², Makoto Nakamura¹³, Yukinori Nakamura¹⁴, Koji Izutsu¹⁵, Junichiro Yuda², Yosuke Minami² (1.Deptartment of Hematology and Oncology, Osaka University, 2.Department of Hematology, National Cancer Center Hospital East, 3.Department of Hematology, Tokyo Medical University Hospital, 4.Div. Hematology, Japanese Red Cross Nagoya First Hospital, 5.Blood Disorders Center, Aiiku Hospital, 6.Department of Hematology/Cell Therapy, Aichi Cancer Center, 7.Division of Hematology/Oncology, Kyoto Prefectural University of Medicine, 8.Department of Hematology, NTT Medical Center Tokyo, 9.Department of Hematology, Kagoshima University Hospital, 10.Department of Hematology, Hamamatsu University Hospital, 11.Department of Hematology/Nephrology/Rheumatology, Akita University, 12.Department of Hematology, Sapporo Medical University, 13.Department of Hematology, Kochi University Hospital, 14.Department of Hematology, Yamaguchi University Hospital, 15.Department of Hematology, National Cancer Center Hospital)